Swiss National Bank Acquires 36,900 Shares of NewAmsterdam Pharma (NASDAQ:NAMS)

Swiss National Bank raised its stake in NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 105.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 72,000 shares of the company's stock after buying an additional 36,900 shares during the period. Swiss National Bank owned 0.08% of NewAmsterdam Pharma worth $1,850,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. FMR LLC boosted its holdings in shares of NewAmsterdam Pharma by 35.6% during the 3rd quarter. FMR LLC now owns 330,412 shares of the company's stock valued at $5,485,000 after acquiring an additional 86,712 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of NewAmsterdam Pharma by 1,231.0% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 239,283 shares of the company's stock valued at $3,972,000 after buying an additional 221,305 shares during the last quarter. JPMorgan Chase & Co. increased its position in NewAmsterdam Pharma by 176.9% during the 3rd quarter. JPMorgan Chase & Co. now owns 22,351 shares of the company's stock valued at $371,000 after purchasing an additional 14,280 shares during the period. State Street Corp grew its holdings in NewAmsterdam Pharma by 168.7% during the 3rd quarter. State Street Corp now owns 37,915 shares of the company's stock worth $629,000 after acquiring an additional 23,805 shares during the period. Finally, Geode Capital Management LLC grew its position in shares of NewAmsterdam Pharma by 1.6% during the 3rd quarter. Geode Capital Management LLC now owns 86,322 shares of the company's stock worth $1,433,000 after buying an additional 1,399 shares during the period. Institutional investors own 89.89% of the company's stock.

Remove Ads

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on NAMS. HC Wainwright reiterated a "buy" rating and issued a $48.00 price target on shares of NewAmsterdam Pharma in a report on Tuesday, January 14th. Royal Bank of Canada reiterated an "outperform" rating and issued a $40.00 price objective on shares of NewAmsterdam Pharma in a research note on Friday, January 24th. Scotiabank lifted their target price on shares of NewAmsterdam Pharma from $47.00 to $52.00 and gave the stock a "sector outperform" rating in a research report on Thursday, February 27th. UBS Group set a $41.00 target price on NewAmsterdam Pharma in a report on Monday, March 3rd. Finally, Needham & Company LLC dropped their price target on NewAmsterdam Pharma from $46.00 to $42.00 and set a "buy" rating on the stock in a report on Thursday, February 27th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, NewAmsterdam Pharma currently has a consensus rating of "Buy" and a consensus target price of $43.33.

NewAmsterdam Pharma Price Performance

Shares of NAMS traded down $0.19 during midday trading on Wednesday, hitting $18.19. 243,995 shares of the company traded hands, compared to its average volume of 544,388. NewAmsterdam Pharma has a one year low of $15.19 and a one year high of $27.29. The firm has a market cap of $2.00 billion, a P/E ratio of -6.99 and a beta of -0.04. The stock has a 50-day moving average of $21.50 and a 200-day moving average of $21.32.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last issued its quarterly earnings data on Wednesday, February 26th. The company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.47). The company had revenue of $12.77 million for the quarter, compared to the consensus estimate of $3.30 million. Sell-side analysts forecast that NewAmsterdam Pharma will post -1.75 EPS for the current fiscal year.

Insider Activity

In related news, CAO Louise Frederika Kooij sold 150,000 shares of the business's stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $20.37, for a total value of $3,055,500.00. Following the completion of the sale, the chief accounting officer now owns 15,000 shares in the company, valued at $305,550. The trade was a 90.91 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director James N. Topper acquired 1,135 shares of the stock in a transaction dated Wednesday, March 26th. The stock was acquired at an average price of $22.49 per share, with a total value of $25,526.15. Following the completion of the acquisition, the director now owns 3,013,569 shares in the company, valued at approximately $67,775,166.81. The trade was a 0.04 % increase in their position. The disclosure for this purchase can be found here. Company insiders own 19.50% of the company's stock.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.